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Abstract
Purpose Two phase I, open-label trials in healthy subjects
assessed whether co-administration with CYP3A4/CYP2C19
inhibitors, itraconazole/fluconazole (study A), or CYP3A4 in-
ducer, rifampicin (study B), affects the exposure, safety/
tolerability and pharmacokinetics of selumetinib and its metab-
olite N-desmethyl selumetinib.
Methods In study A (n = 26), subjects received a single dose
of selumetinib 25 mg and, after 4 days of washout, were ran-
domized to treatment 1 (itraconazole 200 mg twice daily on
days 1–11) or treatment 2 (fluconazole 400 mg on day 1 then
200 mg/day on days 2–11) plus co-administration of single-
dose selumetinib 25 mg on day 8 (selumetinib staggered 4 h
after itraconazole/fluconazole dose); Twenty-one days after
discharge/washout, subjects received the alternate treatment.
In study B (n = 22), subjects received a single dose of
selumetinib 75 mg (day 1) then rifampicin 600 mg/day (days
4–14) plus a single dose of selumetinib 75 mg on day 12.
Pharmacokinetic analysis and safety assessments were
performed.
Results Selumetinib co-administered with itraconazole, flu-
conazole (selumetinib staggered 4 h after itraconazole/
fluconazole dose), or rifampicin was well tolerated.
Selumetinib exposure was higher when co-administered with
itraconazole or fluconazole (area under the plasma
concentration-time curve (AUC) increased by 49 and 53%,
respectively; maximum plasma concentration (Cmax) in-
creased by 19 and 26%, respectively) but lower when co-
dosed with rifampicin (AUC and Cmax decreased by 51 and
26%, respectively) versus selumetinib dosed alone. Co-
administration with itraconazole or rifampicin decreased N-
desmethyl selumetinib AUC(0–t) (11 and 55%, respectively),
and Cmax (25 and 18%, respectively), with fluconazole,
AUC(0–t) increased by 40%, but there was no effect on Cmax.
Conclusions Co-administration of CYP3A4/CYP2C19 inhib-
itors will likely increase exposure to selumetinib, while
CYP3A4 inducers will likely reduce its exposure.
Keywords Selumetinib . Exposure . Cytochrome P450 .
Inhibition . Induction . Pharmacokinetic profile
Introduction
Selumetinib (AZD6244, ARRY-142886) is an oral, potent and
selective, allosteric MEK1/2 inhibitor [1] in clinical develop-
ment for a variety of different tumor types, including a phase
III study in differentiated thyroid cancer [2] (NCT01843062)
and a phase II registration study in neurofibromatosis type 1
[3] (NCT01362803).
Angela Dymond, Paul Martin and David Mathews at the time of study
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In vitro data from reaction phenotyping studies have shown
that selumetinib can undergo metabolism by phase I (mainly
oxidation through cytochrome P450 (CYP) enzymes) and
phase II (conjugation with glucuronides) metabolic pathways
(unpublished data1). CYP3A4 is the pre-dominant isoform
responsible for selumetinib oxidative metabolism with
CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A5 that
is also involved to a smaller extent. CYP3A4, in particular, is
involved in the metabolism of a wide range of compounds,
including various drugs and toxins [4–6]. Exposure of
selumetinib may be influenced by CYP inhibitors or inducers,
in particular by inhibitors or inducers of CYP3A4 or
CYP2C19, potentially affecting the safety profile or efficacy
of selumetinib. Potent CYP3A4 and CYP2C19 modulators
include itraconazole and fluconazole (antifungal agents) and
rifampicin (an antibiotic agent); these agents can be used as
representative inhibitors or inducers of these CYP enzymes.
Itraconazole and fluconazole are not totally selective towards
CYP3A4 and CYP2C19, respectively, but demonstrate the
most potent inhibition of these CYPs. Rifampicin induces
many CYPs but exerts its most potent induction on
CYP3A4. Since selumetinib will be given to patients who
are potentially taking concurrent therapies, which could po-
tentially modify the activity of these enzymes, assessing the
exposure of selumetinib when taken together with such agents
is extremely important for evaluating the effects on the safety
profile and/or efficacy of selumetinib.
Here, we report two clinical trials in healthy subjects
assessing the exposure of selumetinib and its metabolite: N-
desmethyl selumetinib when co-administered with the
CYP3A4 or CYP2C19 inhibitors, itraconazole or fluconazole,
respectively, or the CYP3A4 inducer, rifampicin.
Subjects and methods
Both phase I open-label, single-center trials in healthy subjects
were performed by Quintiles Phase I Services (Overland Park,
KS, USA). The trials were conducted in accordance with the
ethical principles outlined in the Declaration of Helsinki and
the International Conference on Harmonization Good Clinical
Practice. Written informed consent was obtained from all sub-
jects prior to any study-related procedures.
The primary study objectives were to investigate the effects
of the potent CYP3A4 or CYP2C19 inhibitors, itraconazole
200 mg and fluconazole 200 mg (400 mg on first day dose) at
multiple doses, respectively, on the exposure of a single oral
dose of selumetinib 25 mg (NCT02093728), and the effects of
CYP3A4 induction frommultiple 600 mg oral doses of rifam-
picin on the exposure of a single oral dose of selumetinib
75 mg (NCT02046850). Secondary objectives included
assessment of the pharmacokinetics (PKs) of N-desmethyl
selumetinib following co-dosing of selumetinib with
itraconazole, fluconazole, or rifampicin, and the safety and
tolerability of selumetinib.
Subjects
For both studies, healthy male and female (of nonchildbearing
potential) subjects aged 18–45 years, weighing 50–100 kg,
and with a body mass index of 18–30 kg/m2 were eligible
for enrollment. Additional information regarding the inclusion
and exclusion criteria is included as Online Resource 1.
Study design and experimental treatments
A sample size of 20 evaluable healthy subjects was determined
for each trial based on the desire to gain adequate information
while exposing as few healthy subjects as possible to study pro-
cedures. As demonstrated in the expected 90% confidence inter-
vals (CIs) for the geometric least squares mean ratios for area
under the plasma concentration-time curve (AUC) and maxi-
mum plasma concentration (Cmax), this sample size would pro-
vide an adequate precision for the estimation of potential drug-
drug interaction effects. The expected 90% CIs were calculated
using historical data. The within-subject estimates of the coeffi-
cient of variation (CV) were derived from the relative bioavail-
ability trial (NCT01635023) [7] of 16.9% for AUC and 34.0%
for Cmax for selumetinib (manuscript in preparation).
Twenty-six and 24 healthy subjects were planned for en-
rollment into the itraconazole/fluconazole (study A) and ri-
fampicin (study B) studies, respectively, in order to ensure at
least 20 subjects completed each study, assuming an approx-
imate dropout rate of 20%.
Selumetinib 75 mg is the intended therapeutic dose and the
maximum dose permitted in Western healthy subjects. A low-
er dose of selumetinib, 25 mg, was used in the itraconazole/
fluconazole trial to limit any increased exposure of
selumetinib resulting from potential drug-drug interactions,
to below the normal exposure at 75 mg. In both trials, the
formulation of selumetinib used was identical to that in the
ongoing phase III studies (oral capsules, containing 25 mg
freebase, equivalent of selumetinib Hyd-Sulfate; Patheon,
Cincinnati, USA).
Itraconazole/fluconazole trial (study A)
The phase I, open-label, single-center, double-crossover-se-
quence, partially randomized (for assignment to treatment se-
quence), three-period itraconazole/fluconazole trial consisted of
four visits to the study center (Fig. 1a). Subjects were screened
during visit 1, which is 28 days prior to visit 2.
On day 1 of visit 2, subjects were randomized to one of two
treatment sequences and admitted for residence at the study1 Report no. Be000021-21, data on file, AstraZeneca, Cheshire, UK
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center up to day 12; standardized meals were provided
during residency. During dosing period 1, all subjects
received a single dose of selumetinib 25 mg followed
by a 4-day washout period. In dosing period 2, during
days 1–11, subjects received either itraconazole (200 mg
twice daily) or fluconazole (a 400 mg loading dose on
day 1 followed by 200 mg once daily thereafter); all
subjects received a second dose of selumetinib 25 mg
on day 8. Safety assessments were performed, and
blood samples were collected for PK analysis up until
Treatment E: 
selumetinib + fluconazole (n=10)
A morning dose of 200 mg fluconazole 
followed by a single dose of 
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(4 hours fasted state) on Day 8. 
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fluconazole on Day 8 to Day 11
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Treatment D: fluconazole (n=10)
400 mg fluconazole on Day 1 and daily
doses of 200 mg fluconazole on 
Day 2 to Day 7
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Treatment B: itraconazole (n=11)
Twice daily doses of 200 mg
itraconazole on Day 1 to Day 7
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Day 8 to Day 11
Period 1 
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Washout period of 21 days 
following last dose of itraconazole
Washout period of 4 days
Discharge on Day 12: 
Washout period of 21 days 
following last dose of fluconazole
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Treatment A: selumetinib alone (n=13)
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(4 hours fasted state) on Day 1
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200 mg itraconazole on Day 8 to Day 11
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Single oral dose of 
75 mg selumetinib on Day 1
Treatment B:
rifampicin alone (n=22)
600 mg rifampicin daily for 8 days 
from Days 4 to 11
Treatment C:
rifampicin + selumetinib (n=22)
600 mg rifampicin daily on 
Days 12 to 14, with 
75 mg selumetinib on Day 12
Follow up
(n=22)
7 to 10 days after 
discharge on Day 15





Itraconazole/fluconazole trial (Study A) Rifampicin trial (Study B)
Fig. 1 Design of study A (itraconazole and fluconazole (a)) and study B (rifampicin (b)). Asterisk indicates that selumetinib staggered 4 h after
itraconazole/fluconazole dose
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day 12. Subjects were discharged on day 12 and com-
pleted a washout period of at least 21 days.
During visit 3, dosing period 3 comprised days 1–11 when
subjects received the alternate treatment regimen (fluconazole
400 mg on day 1 followed by 200 mg once daily thereafter or
itraconazole 200 mg twice daily) in a crossover fashion. All
subjects received a second dose of selumetinib of 25 mg on
day 8. Subjects were discharged on day 12. A follow-up visit,
visit 4, was scheduled for 7–10 days after discharge from the
study center.
Dose regimens for itraconazole and fluconazole were selected
following consideration of the product Summary of Product
Characteristics (SPCs) [8, 9] and internal expertise with the aim
of maximizing the inhibitory effects on CYP3A4 and CYP2C19
while limiting exposure to the agents as appropriate. Subjects
were administered with accepted clinical regimens of
itraconazole (200mg twice daily) or fluconazole (a 400mg load-
ing dose and 200 mg daily thereafter), respectively, for 7 days
prior to selumetinib. Continued dosing of itraconazole or flucon-
azole for a further 3–4 days after selumetinib dosing ensured that
the maximum enzyme inhibitory effects were maintained during
the selumetinib sampling period. Selumetinib was administered
4 h after a light breakfast (approximately 4 h after the
itraconazole or fluconazole dose), and subjects continued to fast
at least 4 h post-dose. Fluids were not allowed from 1 h pre- until
1 h post-dose, with the exception of 240mLwater to swallow the
capsules. Fluconazole was dosed with a light breakfast; there
were no restrictions regarding dosing with food in the SPC [8].
Itraconazole was dosed with a light breakfast and dinner as per
SPC guidelines to ensure complete absorption [9].
Rifampicin trial (study B)
The rifampicin open-label, fixed-sequence, single-center trial
consisted of three visits to the study center (Fig. 1b). Subjects
were screened during visit 1, which is 28 days prior to visit 2.
During visit 2, subjects received a single oral dose of selumetinib
75 mg (3 × 25 mg capsules) on day 1 and resided at the study
center up to day 15. On day 4, daily oral rifampicin 600 mg
(capsule) was commenced and continued up to day 14, with a
further single dose of selumetinib 75 mg co-administered (at the
same time) on day 12. Safety assessments were performed, and
blood samples were collected for PK analysis up until day 15.
Subjects were discharged from the study center on day 15. The
final visit, visit 3, was for follow-up and took place 7–10 days
after discharge.
Subjects received daily dosingof rifampicin 600mg for 8 days
to maximize the induction effect on CYP3A4 [10]. Selumetinib
75 mg was administered in a fasted state; subjects were main-
tained in a fasted state overnight, for a minimum of 10 h until 4 h
post-dose. Similarly, subjects were required to fast for at least
10 h prior to rifampicin administration and remained in the fasted
state for a further 1 h post-dose. Fluids were not allowed from 1 h
pre- until 1 h post-dose, with the exception of water needed to
swallow investigational products.
Pharmacokinetic assessments
Serial blood samples (2 mL) to measure plasma selumetinib
PK in the rifampicin trial were collected pre-selumetinib ad-
ministration (0 h) and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0,
6.0, 8.0, 12.0, 24.0, 36.0, 48.0, and 72.0 h post-dose on days
1–4 and 12–15. The itraconazole/fluconazole trial included
additional sampling time points, at 3.5 and 96.0 h post-
selumetinib administration on days 1–5 of period 1 and days
8–12 of periods 2 and 3. Blood samples were collected prior to
itraconazole or fluconazole administration on days 6 to 8 to
determine trough itraconazole or fluconazole concentrations;
rifampicin concentrations were measured at 2 h post-dose. In
study B, the 4β-hydroxycholesterol to cholesterol concentra-
tion ratio was calculated as a biomarker of CYP3A4 induc-
t i o n . B l o od s amp l e s ( 4 mL ) t o me a s u r e 4β -
hydroxycholesterol and cholesterol prior to administration of
rifampicin or selumetinib were collected on day 12 and before
rifampicin administration on days 4 and 14. Samples were
analyzed by Covance on behalf of AstraZeneca R&D, using
an appropriate bioanalytical method [e.g., 11, 12]. Additional
information regarding the pharmacokinetic assessments, in-
cluding bioanalytical methodology and assay performance,
is included as Online Resource 2.
Safety and tolerability
Adverse events (reported by system organ class and preferred
term using the Medical Dictionary for Regulatory Activities
(MedDRA) version 17.0), vital signs, 12-lead electrocardio-
grams (ECGs), and clinical laboratory tests were recorded to
assess safety and tolerability in both trials. Adverse events
were collected from day 1, period 1 of visit 2, until the
follow-up visit in each trial. Serious adverse events were col-
lected from the time of informed consent until follow-up. Each
adverse event was assigned to the period of study treatment in
which it started or worsened. Additional information regard-
ing safety and tolerability is included as Online Resource 3.
Results
Trial populations
Twenty-six and 22 healthy subjects were enrolled in the
itraconazole/fluconazole and rifampicin studies, respectively
(Online Resource 4 illustrates the passage of subjects through
the studies). Subjects in both trials had an age range of 18–
44 years, and the majority were male (>90%) and of similar
mean body mass index (26 kg/m2). Approximately half of all
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subjects in the itraconazole/fluconazole and rifampicin trials
were White (50.0 and 45.5%, respectively) and half were
Black/African Americans (50 and 45.5%, respectively); in
the rifampicin trial, one subject (4.5%) was classed as
American Indian/Alaska Native and one subject (4.5%) was
classed as “Other.”
In the itraconazole/fluconazole trial, all 26 subjects were
randomized to one of two treatment sequences and all re-
ceived study treatment. Twenty-one subjects (80.8%) com-
pleted all treatment sequences, and 20 (76.9%) completed
the study (one subject was lost to follow-up). Five subjects
discontinued partway through the study; three subjects
(11.5%) had protocol deviations (two subjects receiving
selumetinib/itraconazole in period 2; one subject receiving
selumetinib/fluconazole in period 2), one (3.8%) violated the
study site rules (the subject left and returned to the premises
unescorted and unannounced during residential stay in period
2, fluconazole pre-dosing), and one withdrew consent (during
period 2 selumetinib/itraconazole co-administration). In the
rifampicin trial, all 22 (100%) subjects received single-
sequence treatment and completed the study.
Pharmacokinetic results
Selumetinib co-dosed with itraconazole
Trough plasma itraconazole concentration was well above
CYP3A4 IC50 values [13], ranging from 595 to 776 ng/mL
(geometric mean) on days 6 to 8, indicating that sufficient
exposure for inhibition of CYP3A4 was achieved.
Selumetinib exposure increased when co-dosed with
itraconazole (Fig. 2a; Table 1). AUCwas increased by approx-
imately 49% (90% CI 40.4, 58.8), and Cmax was increased by
approximately 19% (90% CI 4.2, 34.9) (Table 2). Co-dosing
Treatment A selumetinib (n=26)
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Treatment A selumetinib (n=22)
Treatment C selumetinib + rifampicin (n=22)
Treatment E selumetinib + fluconazole (n=22)
Fig. 2 Geometric mean plasma concentrations (ng/mL) versus time of
selumetinib (a) and N-desmethyl selumetinib (b) following single doses
of selumetinib, and selumetinib co-dosed with itraconazole or
fluconazole, and of selumetinib (c) and N-desmethyl selumetinib (d)
following single doses of selumetinib, or selumetinib co-dosed with
rifampicin. a, b Treatment A: 25 mg selumetinib alone on day 1,
treatment C: 200 mg itraconazole twice daily on day 8 through day 11
plus 25 mg selumetinib on day 8, treatment E: 200 mg fluconazole once
daily on day 8 through day 11 plus 25 mg selumetinib on day 8. c, d
Treatment A: a single oral dose of 75 mg (3 × 25 mg) selumetinib
administered under the fasted state on day 1, treatment C: a single daily
oral dose of 600 mg rifampicin on days 12 to 14, with 75 mg selumetinib
on day 12 under the fasted state
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with itraconazole also prolonged selumetinib mean terminal
half-life (t1/2 ) by ~6 h and decreased apparent systemic clear-
ance (CL/F) by approximately one third (Table 1).
Itraconazole co-administration resulted in an initial de-
crease in N-desmethyl selumetinib concentrations compared
to selumetinib alone, but beyond the 2 h post-administration,
concentrations were similar (Fig. 2b). Additionally, N-
desmethyl selumetinib AUC(0–t) and Cmax were decreased
with co-dosing of selumetinib and itraconazole comparedwith
selumetinib alone by 11 (90% CI 4.0, 18.0) and 25% (90% CI
15.5, 33.3), respectively (Table 2). Itraconazole decreased the
mean selumetinib metabolite to parent Cmax and AUC(0–t) ra-
tios (Table 1).
Compared with administration of selumetinib alone, co-
dosing with itraconazole did not influence median selumetinib
time to Cmax (tmax); median difference in N-desmethyl
selumetinib tmax was 0.25 (0.00, 0.50 h; P = 0.0366). This
delay was considered not clinically relevant.
Selumetinib co-dosed with fluconazole
Trough plasma fluconazole concentration was generally within
the CYP2C19 IC50 values [14], ranging from 5590 to 5730 ng/
mL (geometric mean) on days 6 to 8, indicating that sufficient
exposure for inhibition of CYP2C19 was achieved. Selumetinib
exposure was increased when co-dosed with fluconazole com-
pared with selumetinib alone (Fig. 2a; Table 1). AUC was in-
creased by 53% (90%CI 43.9, 63.3), andCmaxwas increased by
26% (90% CI 9.9, 43.4) (Table 2). Additionally, mean t1/2 of
selumetinib was slightly prolonged by ~1.5 h and the mean CL/
F was decreased by approximately one third (Table 1).
Fluconazole co-administration resulted in an increase in N-
desmethyl selumetinib compared with selumetinib alone
(Fig. 2b; Table 1). AUC(0–t) was increased by 40% (90% CI
29.1, 52.0), but there was no effect on Cmax (Table 2). Only
minor differences in the metabolite to parent ratios for Cmax
and AUC were detected (Table 1).
Compared with administration of selumetinib alone, co-
dosing with fluconazole did not impact median selumetinib
tmax; median difference in N-desmethyl selumetinib tmax was
0.25 h (0.00, 0.26 h; P = 0.0340). This difference was not
considered clinically relevant.
Selumetinib co-dosed with rifampicin
Steady state rifampicin concentrations were achieved on the
trial, as shown by levels similar to those reported in a previous
study using similar doses of rifampicin [15] and the similar
rifampicin concentrations across study days 7, 9, and 14 at 2 h
post-dose (mean ± standard deviation (SD) 8820 ± 1870,
7960 ± 1660, and 7900 ± 1690 ng/mL, respectively).
The 4β-hydroxycholesterol/cholesterol ratio (a biomarker of
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(3.8-fold), following 9 and 11 days of continuous rifampicin ad-
ministration, respectively, when compared to day 4 (pre-rifampi-
cin).This increase indicated that rifampicinproducedanadequate
level of CYP3A4 induction to assess the effect on selumetinib
exposure.
Selumetinib PK parameters following each treatment are
summarized in Table 1, with statistical comparison of key PK
exposure parameters summarized in Table 2. Selumetinib ex-
posure was lower when co-dosed with rifampicin compared
with selumetinib alone (Fig. 2c; Table 1). AUC was decreased
by 51% (90% CI 47.4, 54.1), and Cmax was reduced by 26%
(90% CI 16.7, 34.1) (Table 2).
N-desmethyl selumetinib exposure was lower when
selumetinib was co-administered with rifampicin (Fig. 2d;
Table 1), with a decrease of 55% (90% CI 50.9, 58.1) in
AUC(0–t) and 18% (90% CI 6.4, 28.8) in Cmax (Table 2).
The decrease in N-desmethyl selumetinib plasma concentra-
tions when co-administered with rifampicin compared with
dosing alone was in proportion to the parent (Fig. 2c, d);
hence, metabolite to parent mean ratios for AUC and Cmax
were not affected by co-dosing with rifampicin (Table 1).
Median selumetinib tmax was not affected by co-dosing
with rifampicin (Table 1). Compared with selumetinib
dosing alone, rifampicin co-administration resulted in an
approximate 2.5 h shorter mean selumetinib t1 /2
(9.27 ± 2.57 vs 6.69 ± 2.33 h) and a twofold increase in
mean CL/F (Table 1).
N-desmethyl selumetinib tmax was slightly decreased
when selumetinib was co-dosed with r i fampicin
(Table 1). N-desmethyl selumetinib concentrations were
measurable to later time points when selumetinib was ad-
ministered alone than when co-administered with rifampi-
cin where concentrations were not quantifiable beyond 8 h
post-dose. Hence, N-desmethyl selumetinib terminal t1/2
estimation with rifampicin co-administration was less ro-
bust and is not presented here.
Adverse effects
No serious adverse events were reported during the
itraconazole/fluconazole or the rifampicin PK studies in 48
subjects in total, and no subjects discontinued treatment due
to adverse events.
In the itraconazole/fluconazole trial, 13/26 subjects (50%)
reported at least one adverse event during the study. There
were no major differences in incidence of adverse events re-
ported in each treatment group. The highest number of ad-
verse events was reported in subjects during treatment with
selumetinib co-dosed with itraconazole (n = 7/24; 29.2%),
with headache (n = 4/24; 16.7%) being the most commonly
reported adverse event in this treatment group. Five subjects
(5/24; 20.8%) reported adverse events during itraconazole-
only treatment, four each during fluconazole only (4/23;
17.4%) and selumetinib co-dosed with fluconazole treatment
(4/22; 18.2%), and two (2/26; 7.7%) during selumetinib-only
treatment. The majority of all reported adverse events were
considered mild in severity by the investigators. One subject
(4.2%) reported a moderate adverse event, which is headache,
during treatment with selumetinib co-dosed with itraconazole.
Overall, three subjects (11.5%) reported adverse events
considered related to selumetinib treatment by the investiga-
tor; diffuse alopecia and headache, both of mild severity, were
each reported in one subject (n = 2; 8.3%) during selumetinib
and itraconazole co-dosing, and acne of mild severity was
reported in one (4.5%) different subject during selumetinib
co-dosed with fluconazole. Only one case of diffuse alopecia
in the selumetinib co-dosed with itraconazole group and one
case of vessel puncture site hemorrhage in the selumetinib co-
dosed with fluconazole group, both of mild severity, were not
resolved by the end of the study.
In the rifampicin trial, all 22 subjects (100%) reported at
least one adverse event; all adverse events were mild in sever-
ity and considered unrelated to selumetinib treatment.
Adverse events were reported in all subjects during the period
of rifampicin administration (days 4–11); chromaturia was
reported by all of these subjects and resolved 2 to 3 days after
rifampicin treatment was ceased. Chromaturia in subjects ad-
ministered rifampicin was, as expected, in line with the SPC
[16]. Four subjects (18.2%) reported at least one adverse event
during selumetinib-only treatment (arthralgia, n = 1; diarrhea,
n = 1; increased alanine aminotransferase, n = 1; pruritus,
n = 1), and one subject (4.5%) reported at least one adverse
event (erythema, n = 1) during selumetinib co-dosed with
rifampicin. All of the adverse events were considered to be
mild in intensity and resolved by the end of study completion.
No clinically significant or relevant trends or changes in
clinical laboratory parameters, vital signs, ECGs, ophthalmo-
logical or physical assessments were detected in either trial.
Discussion
The drug-drug interaction (DDI) studies provide valu-
able knowledge into the potential treatment interactions
during drug polypharmacy or concurrent medication use
[17]. Such drug interactions may influence treatment
safety and efficacy of the primary agent due to altered
drug exposure and may provide important treatment
considerations in the label.
In vitro data showed selumetinib to be mainly metabolized
by CYP3A4 and CYP2C19; hence, it is important to under-
stand whether the inhibition or induction of either of these
enzymes influences selumetinib exposure in the clinic. With
this in mind, a key objective for the phase I drug-drug inter-
action studies described was to assess the effect on the expo-
sure of selumetinib following co-administration with either
182 Eur J Clin Pharmacol (2017) 73:175–184
the CYP3A4 inhibitor itraconazole, the CYP2C19 inhibitor
fluconazole, or the CYP3A4 inducer rifampicin, in healthy
subjects. All of these agents have known potent enzyme mod-
ifying activities against these CYPs but can also modulate
other CYPs. Results showed that selumetinib AUC increased
by ~50% when co-administered with either itraconazole
(CYP3A4 inhibitor) or fluconazole (CYP2C19 inhibitor),
and that selumetinib AUC was decreased by ~50% by the
CYP3A4 inducer rifampicin. These findings are in agreement
with the in vitro data suggesting the involvement of these
enzymes in the metabolism of selumetinib.
Inhibition of CYP3A4 by itraconazole or CYP2C19 by
fluconazole affected levels of the metabolite, N-desmethyl
selumetinib, differently. Co-administration of itraconazole re-
sulted in a decrease in N-desmethyl selumetinib Cmax (~25%)
and AUC0–t (~10%), indicating that CYP3A4 is involved in
the formation of N-desmethyl selumetinib. This was also
reflected in a decrease in the ratio of metabolite to parent for
peak concentration (MRCmax) and overall exposure
(MRAUC(0–t)) when selumetinib was co-administered with
itraconazole than on its own.
Co-administration of fluconazole with selumetinib did not
affect N-desmethyl selumetinib Cmax, while AUC(0–t) was in-
creased, by about 40%. With the inhibition of the CYP2C19
metabolic pathway by fluconazole, more N-desmethyl metab-
olite may have formed via an alternative metabolic route. This
is also reflected in the generally unchanged mean metabolite
to parent exposure ratios for Cmax and AUC(0–t) with flucon-
azole co-administration, suggesting minimal involvement of
CYP2C19 in the formation of N-desmethyl selumetinib.
A similar decrease in N-desmethyl selumetinib exposure to
selumetinib exposure was observed when selumetinib was co-
administered with rifampicin, indicating that CYP3A4 is also
involved in N-desmethyl selumetinib metabolism. As rifam-
picin is also an inducer of other CYP450 enzymes to varying
degrees [18, 19], including CYP2C19, the increase in
selumetinib and N-desmethyl selumetinib metabolism may
be due to a combination of both CYP3A4 and CYP2C19
inductions and potentially via other CYPs as well.
The dose of selumetinib was specifically selected to ac-
count for the potential changes in exposure on co-dosing with
these potent CYP enzyme modifying agents; the resulting
altered selumetinib AUC and Cmax values did not exceed the
safety exposure limit for healthy subjects that was derived
from exposures in patients at the phase III selumetinib dose
of 75 mg twice daily. No safety concerns were identified be-
tween treatment groups.
The study design of the itraconazole and fluconazole trial
proved efficient, using the same control arm for both treat-
ments with no marked complications in recruitment or subject
dropout. Moreover, there were no treatment discontinuations
due to any adverse event. Observed adverse events were con-
sistent with the safety profile of selumetinib and the additional
study treatments. Selumetinib was well tolerated administered
as either a single dose or when co-administered with
itraconazole, fluconazole, or rifampicin. There were three ad-
verse events (alopecia, headache, and acne, which were all of
mild severity) considered related to selumetinib in the
itraconazole/fluconazole trial and none in the rifampicin trial.
In the PK trials discussed, results using the CYP mod-
ulator probes for inhibition of CYP3A4 (itraconazole) or
CYP2C19 (fluconazole), or induction of CYP3A4 (rifam-
picin), are informative of the potential exposure profile
for selumetinib when co-administered with other
CYP3A4/CYP2C19 inhibitors and CYP3A4 inducers in
the clinical setting and, thus, are useful tool probes. By
administering potent CYP3A4/CYP2C19 inhibitors and
CYP3A4 inducers over a prolonged, multiple-dose regi-
men, this likely reflects a “worst case” situation for drug-
drug interactions. The results presented here are encour-
aging and show that changes in the PK of selumetinib
are relatively small (~50%). That said, the clinical sig-
nificance of these potential changes will need to be con-
sidered together with safety and efficacy data from piv-
otal trials to determine any advice such as caution, addi-
tional monitoring, or dose adjustment that may be appro-
priate when co-administration is indicated.
A potential limitation of the current studies is that
selumetinib was administered as a single dose (25 or
75 mg), alone, or in combination with one other treatment in
healthy subjects. In the clinical setting, patients are likely to
receive one or more treatments as multiple doses. However,
despite this limitation, the data collected are sufficient to pro-
vide appropriate guidance in the drug label.
Another potential limitation was the separation of the
itraconazole/fluconazole dosing versus selumetinib dosing to
accommodate fed/fast advice for the respective treatments.
Whilst it is not ideal to have this separation, it is not expected
that the somewhat reduced itraconazole/fluconazole exposure
at the time the selumetinib was dosed would diminish the
inhibitory effects or the measured DDI too much, and it is
believed that the data give a realistic assessment of the DDI
risk.
Conclusion
Co-administration of the potent CYP3A4 inhibitor,
itraconazole, or the potent CYP2C19 inhibitor, fluconazole,
with selumetinib increased selumetinib exposure by ~50%.
Thus, concomitant administration of potent CYP3A4 or
CYP2C19 inhibitor with selumetinib may require caution.
Co-administration of the potent CYP3A4 inducer, rifampicin,
with selumetinib reduced exposure to selumetinib by ~50%.
These study findings will be used to advise patient use in the
clinical setting.
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